Abstract: Histidine-stabilized immunoglobulin preparations and a method for their manufacture are disclosed. The present invention is particularly well suited for stabilization of human gamma globulin (IgG) preparations having a relatively low protein content. Preferred stabilized human gamma globulin preparations comprise about 5 wt-% or less gamma globulin, histidine at a concentration of about 0.025M to about 0.2M, and optionally glycine at a concentration of about 0.05M to about 0.5M. The pH value of the preparations is at least 6.0 but not more than 7.0. A pH value of about 6.4 is most preferred. Conductivity of the preparations is about 2 to about 4 millisiemens at 5.degree. C., preferably about 2.5 to about 3.5 millisiemens at 5.degree. C., and most preferably about 2.7 millisiemens at 5.degree. C.

Abstract: Methods for producing from human plasma or serum, human gamma globulin free of hepatitis-B-virus infectivity and products resulting therefrom. Specifically provided are ion exchange resin/buffer systems capable of effectively removing the virus.

Abstract: Methods for producing from human serum, human gamma globulin essentially free of HB.sub.s Ag and products resulting therefrom. Specifically provided are ion exchange resin/buffer systems capable of effectively removing HB.sub.s Ag thought to be closely correlated with viral hepatitis type B infectivity. Additional steps can include ultrafiltration to increase reduction of any virus not removed in the column passage as well as the addition of anti-HB.sub.g to substantially eliminate all infectivity.

Abstract: Disclosed is a procedure for conducting anti-thrombin III assays in which the conventional thrombin-anti-thrombin III treatment step is conducted at a pH of 7.9 to 8.5 maintained at the level by a buffer system comprising a buffering amount of N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid, N-2-hydroxyethylpiperazine-N'-3-propanesulfonic acid, N-tris-(hydroxymethyl)-methyl-2-amino-ethanesulfonic acid, N-tris-(hydroxymethyl)-methylglycine, or N,N-bis (2-hydroxymethyl)-glycine or a salt thereof. The compositions may also contain bacteriostatic agents.